458
Participants
Start Date
June 30, 2013
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
insulin degludec
Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
insulin degludec
Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
insulin degludec
Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Novo Nordisk Investigational Site, Chuo-ku, Tokyo
Novo Nordisk Investigational Site, Chuo-ku, Tokyo
Novo Nordisk Investigational Site, Fukui-shi, Fukui
Novo Nordisk Investigational Site, Fukuoka
Novo Nordisk Investigational Site, Gifu-shi, Gifu
Novo Nordisk Investigational Site, Izumisano
Novo Nordisk Investigational Site, Kagoshima-shi, Kagoshima
Novo Nordisk Investigational Site, Kamakura-shi
Novo Nordisk Investigational Site, Kashiwara-shi, Osaka
Novo Nordisk Investigational Site, Katsushika-ku, Tokyo
Novo Nordisk Investigational Site, Kawasaki-shi, Kanagawa
Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka
Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka
Novo Nordisk Investigational Site, Kitakyusyu-shi, Fukuoka
Novo Nordisk Investigational Site, Koriyama-shi, Fukushima
Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto
Novo Nordisk Investigational Site, Mito-shi, Ibaraki
Novo Nordisk Investigational Site, Miyazaki
Novo Nordisk Investigational Site, Naka-shi, Ibaraki
Novo Nordisk Investigational Site, Niigata-shi, Niigata
Novo Nordisk Investigational Site, Nishinomiya-shi, Hyogo
Novo Nordisk Investigational Site, Okawa-shi, Fukuoka
Novo Nordisk Investigational Site, Osaka-shi, Osaka
Novo Nordisk Investigational Site, Oyama-shi, Tochigi
Novo Nordisk Investigational Site, Ōita
Novo Nordisk Investigational Site, Sakaide-shi, Kagawa
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Sendai
Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi
Novo Nordisk Investigational Site, Suita-shi, Osaka
Novo Nordisk Investigational Site, Takatsuki-shi, Osaka
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Yokkaichi-shi, Mie
Lead Sponsor
Novo Nordisk A/S
INDUSTRY